Belumosudil is a selective ROCK2 inhibitor that simultaneously targets both the inflammatory and the fibrotic processes of cGVHD (only rebalancing of T cells is depicted in image).1,2
Footnotes: Bcl6, B-cell lymphoma 6; cGVHD, chronic graft-versus-host disease; Foxp3, forkhead box protein P3; IL-17, interleukin 17; IL-21, interleukin 21; IRF4, interferon regulatory factor 4; JAK2, Janus-associated kinase 2; JAK3, Janus-associated kinase 3; ROCK2, rho-associated coiled-coil–containing protein kinase-2; RORγt, retineic-acid-receptor–related orphan nuclear receptor gamma t; STAT3, signal transducer and activator of transcription 3; STAT5, signal transducer and activator of transcription 5; Tfh, follicular helper T [cell]; Th17, type 17 helper T [cell]; Treg, regulatory T [cell].
References: 1. Zanin-Zhorov A et al. Proc Natl Acad Sci USA. 2014;111(47):16814-16819. doi:10.1073/pnas.1414189111 2. Flynn R et al. Blood. 2016;127(17):2144-2154. doi:10.1182/blood-2015-10-678706